Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.4301 USD 2.54%
Market Cap: 107.6m USD
Have any thoughts about
Adagene Inc?
Write Note

Intrinsic Value

ADAG's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ADAG stock under the Base Case scenario is 0.942 USD. Compared to the current market price of 2.4301 USD, Adagene Inc is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADAG Intrinsic Value
0.942 USD
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Adagene Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ADAG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ADAG?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Adagene Inc

Provide an overview of the primary business activities
of Adagene Inc.

What unique competitive advantages
does Adagene Inc hold over its rivals?

What risks and challenges
does Adagene Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Adagene Inc.

Provide P/S
for Adagene Inc.

Provide P/E
for Adagene Inc.

Provide P/OCF
for Adagene Inc.

Provide P/FCFE
for Adagene Inc.

Provide P/B
for Adagene Inc.

Provide EV/S
for Adagene Inc.

Provide EV/GP
for Adagene Inc.

Provide EV/EBITDA
for Adagene Inc.

Provide EV/EBIT
for Adagene Inc.

Provide EV/OCF
for Adagene Inc.

Provide EV/FCFF
for Adagene Inc.

Provide EV/IC
for Adagene Inc.

Show me price targets
for Adagene Inc made by professional analysts.

What are the Revenue projections
for Adagene Inc?

How accurate were the past Revenue estimates
for Adagene Inc?

What are the Net Income projections
for Adagene Inc?

How accurate were the past Net Income estimates
for Adagene Inc?

What are the EPS projections
for Adagene Inc?

How accurate were the past EPS estimates
for Adagene Inc?

What are the EBIT projections
for Adagene Inc?

How accurate were the past EBIT estimates
for Adagene Inc?

Compare the revenue forecasts
for Adagene Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Adagene Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Adagene Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Adagene Inc compared to its peers.

Compare the P/E ratios
of Adagene Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Adagene Inc with its peers.

Analyze the financial leverage
of Adagene Inc compared to its main competitors.

Show all profitability ratios
for Adagene Inc.

Provide ROE
for Adagene Inc.

Provide ROA
for Adagene Inc.

Provide ROIC
for Adagene Inc.

Provide ROCE
for Adagene Inc.

Provide Gross Margin
for Adagene Inc.

Provide Operating Margin
for Adagene Inc.

Provide Net Margin
for Adagene Inc.

Provide FCF Margin
for Adagene Inc.

Show all solvency ratios
for Adagene Inc.

Provide D/E Ratio
for Adagene Inc.

Provide D/A Ratio
for Adagene Inc.

Provide Interest Coverage Ratio
for Adagene Inc.

Provide Altman Z-Score Ratio
for Adagene Inc.

Provide Quick Ratio
for Adagene Inc.

Provide Current Ratio
for Adagene Inc.

Provide Cash Ratio
for Adagene Inc.

What is the historical Revenue growth
over the last 5 years for Adagene Inc?

What is the historical Net Income growth
over the last 5 years for Adagene Inc?

What is the current Free Cash Flow
of Adagene Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Adagene Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Adagene Inc

Balance Sheet Decomposition
Adagene Inc

Current Assets 98.8m
Cash & Short-Term Investments 95.7m
Receivables 31.4k
Other Current Assets 3.1m
Non-Current Assets 2m
PP&E 1.7m
Other Non-Current Assets 281.9k
Current Liabilities 39.5m
Accounts Payable 3.4m
Accrued Liabilities 2.8m
Short-Term Debt 4.2m
Other Current Liabilities 29.1m
Non-Current Liabilities 4.7m
Long-Term Debt 4.6m
Other Non-Current Liabilities 114.1k
Efficiency

Earnings Waterfall
Adagene Inc

Revenue
815.8k USD
Operating Expenses
-37.8m USD
Operating Income
-37m USD
Other Expenses
5.1m USD
Net Income
-31.8m USD

Free Cash Flow Analysis
Adagene Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ADAG Profitability Score
Profitability Due Diligence

Adagene Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
16/100
Profitability
Score

Adagene Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ADAG Solvency Score
Solvency Due Diligence

Adagene Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
48/100
Solvency
Score

Adagene Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADAG Price Targets Summary
Adagene Inc

Wall Street analysts forecast ADAG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADAG is 10.7474 USD with a low forecast of 4.848 USD and a high forecast of 19.7505 USD.

Lowest
Price Target
4.848 USD
99% Upside
Average
Price Target
10.7474 USD
342% Upside
Highest
Price Target
19.7505 USD
713% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ADAG?

Click here to dive deeper.

Dividends

Adagene Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ADAG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Adagene Inc Logo
Adagene Inc

Country

China

Industry

Biotechnology

Market Cap

104.9m USD

Dividend Yield

0%

Description

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Contact

JIANGSU
Suzhou
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
+8651287773632.0
www.adagene.com

IPO

2021-02-09

Employees

198

Officers

Co- Founder, Chairman, CEO and President of R&D
Dr. Peter P. Luo Ph.D.
CFO & Director
Mr. Man Kin Tam M.B.A.
Chief Scientific Officer
Dr. Jc Xu M.D., Ph.D.
Vice President of Investor Relations & Corporate Communications
Ms. Ami Celeste Knoefler
Head of Human Resources
Ms. Ling Zhou
Chief Manufacturing Officer
Dr. Qinghai Zhao
Show More
Senior Vice President of Bioinformatics & Information Technology
Ms. Yan Li M.B.A.
Senior VP & Head of Clinical Operations
Ms. Xiaohong She
Senior Vice President of Early Drug Discovery
Dr. Guizhong Liu Ph.D.
VP & Head of Business Development
Mr. Alexander Goergen
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADAG stock?

The intrinsic value of one ADAG stock under the Base Case scenario is 0.942 USD.

Is ADAG stock undervalued or overvalued?

Compared to the current market price of 2.4301 USD, Adagene Inc is Overvalued by 61%.

Back to Top